Nicotine Addiction: Differential Diagnoses & Workup

References

1. James Jennings. Practical Treatise on the History, Medical Properties, and Cultivation of Tobacco. London, England: SHERWOOD, GILBERT, AND PIPER; 1830:pages 1-10. [Full Text].

2. Esson L, Leeder SR. The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization (WHO); 2004.

3. World Health Organization. Why is tobacco a public health priority? A Tobacco Free Initiative; 2005. Accessed March 30, 2006. [Full Text].

4. Glassman AH, Koob GF. Neuropharmacology. Psychoactive smoke. Nature. Feb 22 1996;379(6567):677-8. [Medline].

5. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport. Jul 2 2002;13(9):1097-106. [Medline].

6. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. Apr 21 2009;150(8):551-5. [Medline]. [Full Text].

7. Richmond RL, Kehoe L, de Almeida Neto AC. Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch. Heart. Dec 1997;78(6):617-8. [Medline].

8. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care. Oct 2000;45(10):1196-9. [Medline].

9. Henningfield JE, Fant RV, Buchhalter AR. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. Sep-Oct 2005;55(5):281-99; quiz 322-3, 325. [Medline].

10. [Best Evidence] Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. Jan 23 2008;CD000146. [Medline].

11. Mahmarian JJ, Moye LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. Jul 1997;30(1):125-30. [Medline].

12. Stotts RC, Roberson PK, Hanna EY. A randomised clinical trial of nicotine patches for treatment of spit tobacco addiction among adolescents. Tob Control. Dec 2003;12 Suppl 4:IV11-5. [Medline].

13. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. Feb 1996;109(2):438-45. [Medline].

14. Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine gum treatment before smoking cessation: a randomized trial. Arch Intern Med. Jun 8 2009;169(11):1028-34. [Medline]. [Full Text].

15. [Guideline] U.S. Department of Health and Human Services. Public Health Service. Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008. [Full Text].

16. Hughes JR, Stead LF, Lancaster T. Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev. 2000;CD000031. [Medline].

17. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. Oct 23 1997;337(17):1195-202. [Medline].

18. [Best Evidence] Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. Jan 24 2007;CD006103. [Medline].

19. Kornitzer M, Boutsen M, Dramaix M. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. Jan 1995;24(1):41-7. [Medline].

20. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. Jan 6 1999;281(1):72-6. [Medline].

21. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. Mar 4 1999;340(9):685-91. [Medline].

22. Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Inst. Aug 18 1999;91(16):1365-75. [Medline].

23. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;CD001009. [Medline].

24. Thomas RE, Baker P, Lorenzetti D. Family-based programmes for preventing smoking by children and adolescents. Cochrane Database Syst Rev. Jan 24 2007;CD004493. [Medline].

25. Thomas R, Perera R. School-based programmes for preventing smoking. Cochrane Database Syst Rev. Jul 19 2006;3:CD001293. [Medline].

26. Sowden AJ, Arblaster L. Mass media interventions for preventing smoking in young people. Cochrane Database Syst Rev. 2000;CD001006. [Medline].

27. Cahill K, Moher M, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst Rev. Oct 8 2008;CD003440. [Medline].

28. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. Jul 20 2005;CD001118. [Medline].

29. Dale LC, Schroeder DR, Wolter TD. Weight change after smoking cessation using variable doses of transdermal nicotine replacement. J Gen Intern Med. Jan 1998;13(1):9-15. [Medline].

30. Allen SS, Hatsukami D, Brintnell DM. Effect of nicotine replacement therapy on post-cessation weight gain and nutrient intake: a randomized controlled trial of postmenopausal female smokers. Addict Behav. Aug 2005;30(7):1273-80. [Medline].

31. Benowitz NL. Sodium intake from smokeless tobacco. N Engl J Med. Sep 29 1988;319(13):873-4. [Medline].

32. Benowitz NL, Jacob P 3rd. Nicotine metabolism in nonsmokers. Clin Pharmacol Ther. Oct 1990;48(4):473-4. [Medline].

33. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE. Jun 25 2008;3(6):e2547. [Medline].

34. Croghan IT, Offord KP, Evans RW, et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc. Oct 1997;72(10):917-24. [Medline].

35. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. Dec 3 1997;278(21):1759-66. [Medline].

36. Dewar AL, Esson L, Entwistle C. Prior learning assessment. Putting experience to the test. Can Nurse. May 2002;98(5):28-31. [Medline].

37. Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. Dec 2007;33(6 Suppl):S318-26. [Medline].

38. Goldstein MG, Niaura R, Willey-Lessne C, et al. Physicians counseling smokers. A population-based survey of patients' perceptions of health care provider-delivered smoking cessation interventions. Arch Intern Med. Jun 23 1997;157(12):1313-9. [Medline].

39. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet. Jun 14 2008;371(9629):2027-38. [Medline].

40. Henningfield JE, Burns DM, Dybing E. Guidance for research and testing to reduce tobacco toxicant exposure. Nicotine Tob Res. Dec 2005;7(6):821-6. [Medline].

41. Hughes JR, Cummings KM, Hyland A. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction. Jan 1999;94(1):109-14. [Medline].

42. Humble C, Croft J, Gerber A, et al. Passive smoking and 20-year cardiovascular disease mortality among nonsmoking wives, Evans County, Georgia. Am J Public Health. May 1990;80(5):599-601. [Medline].

43. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. Dec 12 1996;335(24):1792-8. [Medline].

44. Manley M, Epps RP, Husten C, et al. Clinical interventions in tobacco control. A National Cancer Institute training program for physicians. JAMA. Dec 11 1991;266(22):3172-3. [Medline].

45. Mason RJ, Buist AS, Fisher EB, et al. Cigarette smoking and health. Am Rev Respir Dis. Nov 1985;132(5):1133-6. [Medline].

46. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. Mar 9 2000;342(10):681-9. [Medline].

47. O'Hara P, Connett JE, Lee WW, et al. Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol. Nov 1 1998;148(9):821-30. [Medline].

48. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime. Am J Prev Med. Dec 2007;33(6 Suppl):S340-8. [Medline].

Further Reading

Keywords

smoking cessation, lung cancer, cigarettes, cigarette smoking, chronic obstructive pulmonary disease, COPD, emphysema, atherosclerotic vascular disease, atherosclerosis, nicotine addition, quitting smoking, tobacco addiction, lung disease

Contributor Information and Disclosures

Author

R Gregory Lande, DO, FACN, Clinical Consultant, Army Substance Abuse Program, Department of Psychiatry, Walter Reed Army Medical Center
R Gregory Lande, DO, FACN is a member of the following medical societies: American Osteopathic Academy of Addiction Medicine and American Osteopathic Association
Disclosure: Nothing to disclose.

Medical Editor

Sarah C Aronson, MD, Associate Professor, Departments of Psychiatry and Medicine, Case Western Reserve School of Medicine/University Hospitals of Cleveland
Sarah C Aronson, MD is a member of the following medical societies: American Academy of Family Physicians, American Medical Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories
Eduardo Dunayevich, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.